Abbott says payoff from Mylan deal surges, as Mylan shares leap

April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial $5.3 billion gain from the recent sale to Mylan of its generic drugs business in developed markets outside the United States has jumped to more than $7 billion, thanks to appreciation of Mylan shares it obtained in the deal.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.